Epigenetics of thyroid cancer and novel therapeutic targets.
about
Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancerOncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer.Molecular profiling of thyroid cancer subtypes using large-scale text mining.Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway.The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese PatientsReactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progressionEnhancement of human sodium iodide symporter gene therapy for breast cancer by HDAC inhibitor mediated transcriptional modulation.Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2Environmental epigenetics: a role in endocrine disease?Targeting histone deacetylase in thyroid cancer.Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.Lentivirus-mediated silencing of MPHOSPH8 inhibits MTC proliferation and enhances apoptosis.Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers.PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells.Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line.Histone post-translational modifications induced by histone deacetylase inhibition in transcriptional control units of NIS gene.Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells.5-aza-2'-deoxycytidine has minor effects on differentiation in human thyroid cancer cell lines, but modulates genes that are involved in adaptation in vitro.Diagnostic and prognostic markers in differentiated thyroid cancer.Somatic amplifications and deletions in genome of papillary thyroid carcinomas.Voltammetric behaviour of free DNA bases, methylcytosine and oligonucleotides at disposable screen printed graphite electrode platforms.Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions.Methylation levels of sodium-iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression.Follicular cell-derived thyroid cancer.Interaction between alcohol consumption and methylenetetrahydrofolate reductase polymorphisms in thyroid cancer risk: National Cancer Center cohort in Korea.Detection of global hypermethylation in well-differentiated thyroid neoplasms by immunohistochemical (5-methylcytidine) analysis.Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.PKM2 functions as a potential oncogene and is a crucial target of miR-148a and miR-326 in thyroid tumorigenesis.Role of the Mechanisms of Detection in the Increased Risk of Thyroid Cancer: A Retrospective Cohort Study in an HMO in Buenos AiresE4BP4 promotes thyroid cancer proliferation by modulating iron homeostasis through repression of hepcidinKLF5 promotes the tumorigenesis and metastatic potential of thyroid cancer cells through the NF-κB signaling pathwayCITED1 promotes proliferation of papillary thyroid cancer cells via the regulation of p21 and p27
P2860
Q33603806-9B8AB70C-5E64-447F-A272-DCCEA244CE56Q34808224-73899395-B963-4F11-A203-BC13CE299CE8Q34914970-9E8763E4-2103-439A-B5AA-378790FC795CQ35010507-4597EA56-C33E-4F19-BC5C-56EBD55CE2D9Q35932262-382BA3A0-7A87-4BE4-AD13-920862AB4801Q36486116-68B7C6E8-A403-4205-8292-5BB4E358906FQ36499907-4CE5C7BB-C7BB-4E7A-8CA5-8389E78B379AQ36544687-BFD9C843-A06A-4969-A545-D595B6F5B41FQ37119645-65C724C4-686B-4E93-9B2A-35A60ADA7158Q38066990-2BF24543-B626-4391-B898-CE6D3E18883CQ38675367-D2DA400D-44B9-4F17-94FD-827461BD3EACQ38763963-FF8550CE-B2E8-47C7-9932-46DD2B8FEC9CQ38835322-A1F54F0B-3DB5-467D-A95A-548BA55F85FFQ38891514-4BBC3E1C-B492-4D0C-B1F6-41F37B5180ADQ38907017-04149069-B904-4434-85B0-FE80343B6CFFQ38993423-969264D5-92DF-49B6-AFFC-8293C2C2DFABQ39157582-34976895-385B-43CB-90B4-65277B17E61FQ39241889-B1835F2C-5D29-4C13-A919-EF158249B79EQ40819992-16FE44B2-78A1-48D9-99B1-3D62721B7282Q41088523-20157D0F-E881-467A-B292-183B4C9F8F5DQ44550654-287331C8-E3DD-4878-A69F-484D4063DB90Q44852149-66B4334A-69C1-4D00-96C9-3EBEFC3F5962Q46316325-8B46EF1E-C03F-4DA7-984F-D24CFA1206EDQ48651339-B2324D4E-5C33-4A75-B647-97998EF36431Q52365168-580B6194-0D0F-473E-811D-E54D6BDD9B76Q54171874-AC75B9A5-0683-4D62-92BD-A5F1A0C7CE28Q55058474-B20410D3-6085-4150-9EDF-E39B7BAE38E1Q55712018-100ABAAF-9A97-4683-8433-E2AEE33587CDQ57642079-F77ED27C-3C90-4548-84B7-86A9B8EFA319Q58700293-51335821-69F2-4795-A7F3-51338EE9A514Q58761080-FD003969-6E17-486E-9886-BACC217A63FEQ59137522-9DEB862D-673E-433A-9E03-0A308B21CF6C
P2860
Epigenetics of thyroid cancer and novel therapeutic targets.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Epigenetics of thyroid cancer and novel therapeutic targets.
@en
Epigenetics of thyroid cancer and novel therapeutic targets.
@nl
type
label
Epigenetics of thyroid cancer and novel therapeutic targets.
@en
Epigenetics of thyroid cancer and novel therapeutic targets.
@nl
prefLabel
Epigenetics of thyroid cancer and novel therapeutic targets.
@en
Epigenetics of thyroid cancer and novel therapeutic targets.
@nl
P2093
P356
P1476
Epigenetics of thyroid cancer and novel therapeutic targets.
@en
P2093
Cosimo Durante
Diego Russo
Efisio Puxeddu
Giuseppe Damante
Sebastiano Filetti
P304
P356
10.1530/JME-10-0150
P577
2011-04-28T00:00:00Z